Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn't

Pfizer and Starbucks reportedly lifted their outlooks this summer, but the article cautions that a “louder” recovery is not the same as a “quieter” one for investors managing real cash-flow needs. The message emphasizes dispersion in recovery quality rather than a clear positive fundamental change, implying limited immediate impact without specific numbers or guidance details.